Prosecution Insights
Last updated: August 15, 2026
Application No. 17/920,323

COMPOSITIONS AND METHODS FOR TREATMENT OF ACUTE RESPIRATORY DISTRESS SYNDROME

Non-Final OA §Other
Filed
Oct 20, 2022
Priority
Apr 20, 2020 — provisional 63/012,783 +3 more
Examiner
DARPOLOR, JOSEPHINE KEBBEH
Art Unit
1642
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
Edesa Biotech Research Inc.
OA Round
3 (Non-Final)
64%
Grant Probability
Moderate
3-4
OA Rounds
0m
Est. Remaining
99%
With Interview

Examiner Intelligence

Grants 64% of resolved cases
64%
Career Allowance Rate
20 granted / 31 resolved
+4.5% vs TC avg
Strong +38% interview lift
Without
With
+37.9%
Interview Lift
resolved cases with interview
Typical timeline
3y 6m
Avg Prosecution
10 currently pending
Career history
57
Total Applications
across all art units

Statute-Specific Performance

§101
2.2%
-37.8% vs TC avg
§103
33.0%
-7.0% vs TC avg
§102
15.1%
-24.9% vs TC avg
§112
31.3%
-8.7% vs TC avg
Black line = Tech Center average estimate • Based on career data from 31 resolved cases

Office Action

§Other
Detailed Action Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . A request for continued examination under 37 CFR 1.114, including the fee set forth in 37 CFR 1.17(e), was filed in this application after final rejection. Since this application is eligible for continued examination under 37 CFR 1.114, and the fee set forth in 37 CFR 1.17(e) has been timely paid, the finality of the previous Office action has been withdrawn pursuant to 37 CFR 1.114. Applicant’s submission filed on 07/09/2026 has been entered. Status of Claims Claims 1 is amended. Claims 34 and 48-58 are cancelled. Claims 1, 17, 24, 26, 28-29, 32-33, 35-38, and 40-41 are currently pending and under examination. Priority Applicant’s claim for the benefit of a prior-filed application under 35 U.S.C. 119(e) or under 35 U.S.C. 120, 121, 365(c), or 386(c) is acknowledged. Claims 1, 17, 24, 26, 28-29, 32-33, 35-38, and 40-41 have an effective filing date of 04/20/2020, corresponding to provisional applications 63/012,786 and 63/012,783. Rejections Withdrawn 35 U.S.C. 103 The Affidavit filed 07/09/2026 and the Exhibits submitted in support of the Affidavit have been fully considered and are persuasive. The data presented by Applicant demonstrates that the claimed invention, which requires a 15 mg/kg dose of the claimed anti-TLR4 antibody, is surprisingly safe and efficacious, see p. 7 and 8 of Applicant Arguments, dated 07/09/2026. Therefore the 35 USC 103 rejection is withdrawn. Claim Rejections The following is a quotation of 35 U.S.C. 112(b): (b) CONCLUSION.—The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the inventor or a joint inventor regards as the invention. The following is a quotation of 35 U.S.C. 112 (pre-AIA ), second paragraph: The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention. The term “about” in claims 1 and 33 is a relative term which renders the claim indefinite. The term “about” is not defined by the claim, the specification does not provide a standard for ascertaining the requisite degree, and one of ordinary skill in the art would not be reasonably apprised of the scope of the invention. One of ordinary skill in the art would be unable to determine the metes and bounds of the term “about. Therefore claims 1, 17, 24, 26, 28-29, 32-33, 35-38, and 40-41 are rejected. Conclusion No claims are allowed. Any inquiry concerning this communication or earlier communications from the examiner should be directed to JOSEPHINE K DARPOLOR whose telephone number is (571)272-0115. The examiner can normally be reached 7:30ET-4:30ET. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Samira Jean-Louis can be reached at (571)270-3503. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /J.K.D./Examiner, Art Unit 1642 /NELSON B MOSELEY II/Primary Examiner, Art Unit 1642
Read full office action

Prosecution Timeline

Show 1 earlier event
Oct 20, 2022
Response after Non-Final Action
Jul 16, 2025
Non-Final Rejection mailed — §Other
Oct 16, 2025
Response Filed
Jan 09, 2026
Final Rejection mailed — §Other
Jul 09, 2026
Request for Continued Examination
Jul 09, 2026
Response after Non-Final Action
Jul 12, 2026
Response after Non-Final Action
Aug 06, 2026
Non-Final Rejection mailed — §Other (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12662675
HUMANIZED NOTCH RECEPTORS WITH HINGE DOMAIN
3y 8m to grant Granted Jun 23, 2026
Patent 12648995
FULLY HUMANIZED BISPECIFIC CHIMERIC ANTIGEN RECEPTOR TARGETING CD19 AND CD22 AND USE THEREOF
3y 5m to grant Granted Jun 09, 2026
Patent 12630621
HUMANIZED MONOCLONAL ANTIBODY AGAINST cANGPTL4
3y 6m to grant Granted May 19, 2026
Patent 12617858
ANTI-MULLERIAN HORMONE RECEPTOR 2 ANTIBODIES AND METHODS OF USE
3y 9m to grant Granted May 05, 2026
Patent 12618838
SINGLE DOMAIN VHH ANTIBODIES AGAINST SARS-COV-2 VIRUS
3y 5m to grant Granted May 05, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

3-4
Expected OA Rounds
64%
Grant Probability
99%
With Interview (+37.9%)
3y 6m (~0m remaining)
Median Time to Grant
High
PTA Risk
Based on 31 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month